Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m
This article was originally published here
As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around
The post Jazz Pharmaceuticals buys biotechnology firm Cavion for £259m appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!